Additionally, in a study, after resistance to RET inhibitors, 15% of RET fusion NSCLC patients developed MET gene amplification, while only 10% of patients developed resistance through secondary mutations in the RET gene, demonstrating that MET gene amplification is also one of the most common causes of resistance to RET inhibitors (77). This evidence concerns the gene MET and non-small cell lung carcinoma.